Flaharty Asset Management LLC Has $1.10 Million Stock Holdings in Eli Lilly and Company $LLY

Flaharty Asset Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,406 shares of the company’s stock after selling 90 shares during the quarter. Flaharty Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,096,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. PNC Financial Services Group Inc. raised its holdings in Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the period. Wellington Management Group LLP raised its stake in shares of Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after buying an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after buying an additional 682,203 shares during the period. Finally, Nuveen LLC acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,024.67 on Friday. The firm has a market cap of $968.70 billion, a P/E ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,033.62. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm’s 50 day moving average price is $826.89 and its two-hundred day moving average price is $780.87.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period last year, the business posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the stock an “overweight” rating in a report on Thursday. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $999.28.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.